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ABSTRACT
The use of nanoparticles for disease treatment is an increasingly popular area of research.
The potential for multi-functionality allows nanoparticles to be used as transport and delivery
vehicles for drugs and as diagnostic aides, among other applications, to address the unmet needs
of many disease treatments. One such class of disease is osteoporosis including severe disorders,
like Paget’s disease, Osteogenesis Imperfecta and Legg Calve Perthes disease. In this dissertation,
we discuss a nanoparticle system consisting of gold nanoparticles surface functionalized with
primary amine bisphosphonates, which is a classification of pharmaceuticals that is common in
the treatment of osteoporosis. Functionalized nanoparticles allow for greater intracellular
concentrations of pharmaceutical, while the properties of the gold nanoparticles provide the ability
to track the pharmaceutical and enhance imaging.
We have synthesized and characterized bisphosphonate functionalized gold nanoparticles
of controlled size of approximately 15 nm, which are suitable for cellular uptake, and
functionalized the surface using self-assembly with pamidronate and alendronate. In one major
finding of this study, inductively coupled plasma mass spectrometry was used to estimate
approximate surface density of the bisphosphonates on the gold nanoparticles. This resulted in
concentrations of approximately 0.65 molecules per nm2 (approximately 154 Å2/molecule) for
pamidronate functionalized on gold, and approximately 2.6 molecules per nm2 (approximately 39
Å2/molecule) for alendronate functionalized on gold. This allows for more accurate estimates of
pharmaceutical concentrations, during in vitro and in vivo studies.
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Additionally, we investigated the effects of bisphosphonate functionalized gold
nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. We found
that attaching the bisphosphonates to the surface of the nanoparticles leads to increased apoptotic
effects of the bisphosphonates on the osteoclast cells compared to free bisphosphonates. Further,
we showed bisphosphonate functionalized gold nanoparticles may have an effect on nuclei
morphology that may provide an additional means of modulating bone resorption rather than just
through influencing viability. Further we showed that it may be possible to target concentrations
that are safe for osteoblasts, which is critical in determining potential treatment concentrations.
These viability results bring to light a number of potential considerations into the optimization of
potential treatments, such as dosing concentrations.
Finally, detailed results are given on effects of bisphosphonate functionalized gold
nanoparticles on important behavior and activity of osteoclast and osteoblast cells in vitro. We
showed that while using concentrations below the toxicity threshold, some of the normal activity
of the cells could be maintained. RANKL and ALP expression in osteoblasts were maintained
when removing viability as a variable. Additionally, bone nodule formation was also maintained
for osteoblasts and co-cultured in vitro systems. Finally, we showed that the introduction of bone
in the in vitro studies adds a new degree of consideration as to the interaction of the
bisphosphonates with the hydroxyapatite surface. This strong interaction with bone is an important
consideration in further developing potential treatments for osteoporotic disease.
This dissertation provides insights into the use of bisphosphonate functionalized gold
nanoparticles as a potential treatment and means of study for bone remodeling disorders.
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CHAPTER 1:
INTRODUCTION 1
The research described in this dissertation focuses on the study and development of a novel
nanoparticle based system as a potential treatment and means of study for severe osteoporotic
diseases. Towards that end, a brief overview of bone as an organ, as well as the bone remodeling
processes is presented in order to provide context for osteoporotic disorders. Additionally, a brief
description of the standard treatment for osteoporotic disorders is provided as this treatment is
usually a common yardstick when developing new treatments. Towards the main research goal, an
introduction to nanoparticles is given, with a focus on gold nanoparticles, and the properties that
make them attractive for various biomedical applications, especially drug delivery and medical
imaging.
1.1 Bone
Bone is a large, complex organ that makes up the skeleton and is responsible predominantly
for the support and protection of various organs in the body while enabling mobility by acting as
attachment points for muscles, tendons, and ligaments[1]. Bone also acts as a storehouse for
various minerals (like calcium and phosphorus), and is responsible for the production of red and
white blood cells. It is a relative light, but dense hybrid of an active tissue of different cells
supported by mineralized osseous tissue. These cells include osteoblast and osteoclasts, which are
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responsible for bone mineralization and resorption respectively, whereas the osseous tissue is made
up of various inorganic salts as well as collagen[2]. A mature adult will possess approximately 206
[3] separate bones made up of five different types of bone: long, short, flat, sesamoid, and irregular.
Bone has a layered structure made up of the outer cortical bone surrounding inner cancellous bone,
which itself typically contains bone marrow (Figure 1.1).
Cortical bone is relatively hard due to its higher density than cancellous bone, lending to
it also being known as compact bone. This outer layer is what gives bones their outward
appearance and represents approximately 80% by mass of all bone in adults. It is sandwiched
between two connective tissue layers known as the periosteum on its outer surface and the
endosteum on its inner layer. The cortical bone is itself made up of layers of smaller structures
called osteons. These osteon are column like structures organized in the axial direction of the bone,
and are made up of multiple layers of osteoblasts and osteocytes. These layers form around a
central canal call the Haversian canal while other canals known as Volkmann’s canals connect
osteons together in the perpendicular[4].
Cancellous bone, also known as trabecular or spongy bone, is porous, making it much less
dense than cortical bone. This lower density lends to its weaker mechanical properties[1].
Furthermore, its porosity also gives rise to greater surface area (ten times that of cortical bone),
which is why it is where the majority of metabolic activity occurs within the skeletal system.
Cancellous bone typically contains, within the porous structure, bone marrow and hematopoietic
stem cells (which produce platelets, and red and white blood cells) [2], and is highly vascularized.
Cancellous bone is organized through the formation of trabeculae, which are small rod or pillar
like structures formed within the cancellous bone of long bones and oriented in the direction of
mechanical loading[1].
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This brief overview of the organization and importance of bone and the skeletal system as
a whole, should provide some understanding as to the complexity of the organ. This complexity
gives rise to the myriad of issues involved when it comes to disease progression and the
development of potential treatments. This will be important to keep in mind in the following
sections, as we discuss the processes involved in bone remodeling and how disruption of these
processes can lead to osteoporotic disease progression.
1.2 Bone Remodeling and Osteoporotic Diseases
In normal bone development, osteoclast-mediated bone resorption is balanced by
osteoblast-mediated bone formation, resulting in no net loss of bone mass[5]. In severe
osteoporotic diseases, an imbalance between bone resorption and bone growth occurs and can
become dominant for severe diseases, such as, Paget’s disease, Osteogenesis Imperfecta (OI) and
Legg Calve Perthes disease (LCPD). The dominant imbalance between resorption and growth seen
in severe bone diseases can usually be attributed to relative over-activity of osteoclasts.
Osteoclasts are phagocytic cells that share their origin with other dendritic cells and
macrophages. They are differentiated from hematopoietic stem cells derived in bone marrow[6].
Mature osteoclasts are formed by activated precursor osteoclasts that fuse together and form
multinucleated cells. These mature osteoclasts typically possess 5-8 nuclei, though extreme
numbers have been reflected in diseases such as Paget’s[6]. Mature osteoclasts resorb bone by
excreting acid as well as cathepsin K from a ruffled cellular membrane border that increases
surface area to promote bone resorption. This dissolves the hydroxyapatite and fibrillar collagen
that are taken up through the cell membrane and continues to be digested on the way to the
secretory domain (Figure 1.2)[7]. Osteoclast mediated bone resorption is modulated by three major
processes; recruitment, activity and life cycle of osteoclasts. It is here that bisphosphonates
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(discussed in section 1.3) have been shown to act on osteoclasts through reduction of their viability,
inhibition of their recruitment, reduction of their ability to bind to bone, and disruption of their
morphology[5]. Furthermore, these processes are at least partially influenced by osteoblasts[5].
Osteoblasts express proteins that have been shown to be a major factor in the remodeling process
of bone. Osteoblasts express receptor activator of nuclear factor (NF)-κB ligand (RANKL) as well
as osteoprotegerin (OPG) and these two along with RANK, RANKL’s receptor expressed on OC
cells, play a critical role in the three processes of recruitment, binding, and life-cycle. RANKL
binds with RANK expressed on the surface of pre-osteoclast

cells to promote

osteoclastogenesis[8]. OPG, expressed on the surface of osteoblasts, is a competitor protein to
RANK that binds RANKL and helps to modulate the recruitment and differentiation process
(Figure 1.3)[9]. Decreased expression of OPG or increased expression of RANKL could lead to
increased osteoclastogenesis and thus potentially to osteoporosis. It is, therefore, important to
consider the effects any potential treatment will have on this protein system.
1.3 Bisphosphonates and Other Disease Treatments
Bisphosphonates are most commonly used to treat general osteoporosis and in recent years,
systemic delivery of bisphosphonates has also been considered for the treatment of severe
osteoporotic diseases[10]. It is well known that amino-bisphosphonates (n-BP) have a strong
inhibitory effect on osteoclasts, and are considered the strongest clinical inhibitors of bone
resorption. Bisphosphonates were first used clinically to treat Paget’s disease[11].
The bisphosphonates work by inhibiting enzymes in the mevalonate pathway of cholesterol
synthesis[12]. This then leads to the reduction of levels of geranylgeranyl diphosphate. Since
geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)binding proteins that are necessary for osteoclast activity and survival [13, 14], reduction in GTP
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decreases the levels of these binding proteins, thus compromising the viability of the cells. Overall,
bisphosphonates have been shown to reduce osteoclast viability, inhibit osteoclast recruitment,
inhibit osteoclasts-mediated resorption, reduce their ability to bind to bone, and disrupt
morphology[5].
There are two major classes of bisphosphonates: nitrogen-containing bisphosphonates
(nBP) and non-nitrogen-containing bisphosphonates. The P-C-P structure of the bisphosphonate
is strongly adherent to bone and depending on the specific structure of a given bisphosphonate,
their deposition characteristics in bone may differ. For instance, alendronate has been shown to
predominantly bind to bone resorption sites[15]. This strong affinity for bone adsorption leads to
a natural targeting of osteoclasts as they are the only cells capable of resorbing bone[6].
Radiolabeled alendronate in in-vivo studies showed that a majority of the alendronate was uptaken
by osteoclasts and not by other tissues in the body[12].
Although bisphosphonates possess limited targeting capabilities, systematic delivery has
drawbacks. In the case of LCPD, for example, osteonecrosis of the proximal epiphysis of the femur
affects children between the ages of 2-14 years old and early stages of LCPD is marked by the lack
of blood flow that leads to the osteonecrosis[16]. This lack of blood flow makes systemic delivery
an inefficient treatment modality, as very little of the dosage will reach the target area.
Additionally, the systemic delivery of bisphosphonates in the treatment of localized diseases, such
as LCPD, can lead to undesired modulation of the bone remodeling process in other portions of
the body. The most common example of this undesirable modulation is bisphosphonate-related
osteonecrosis of the jaw[17]. This need for a localized delivery method and for a means to track
treatments is a critical consideration in the development of future combination therapies and
diagnostic aides.

5

1.4 Gold Nanoparticles
The phagocytic nature of osteoclasts discussed previously can also be leveraged in the
development of new treatment modalities, through the use of nanoparticles. Nanoparticles have
many properties (electronic, catalytic, optical, and magnetic) that have made them an area of great
interest for applications such as chemical synthesis, photonics, biological diagnostics and various
medical therapies[18-21].
Gold nanoparticles (GNP), for example, have been shown to be highly biocompatible, with
low toxicity[22-24]. Optimization of shape, surface functionality, and size has been investigated
for promoting optimal cellular uptake[25]. Gold nanoparticles have been investigated for use in
drug delivery applications for cancer treatment with promising results[26]. Additionally, they have
shown promising results as antimicrobial agents[22]. These features of GNP and the phagocytotic
nature of osteoclast cells provide a potential route for the localized delivery. Further localization
may also be achieved, either through direct delivery methods, such as intra-osseous injection
directly into the avascular region as has been shown [27] in the case of LCPD, or through additional
functionalization with a targeting agent[28].
Additionally, the properties of GNP make it ideal for image enhancement as well as other
tracking and sensing techniques that would allow for the study of the disease and treatment
progression. One such property is known as localized surface plasmon resonance (LSPR). LSPR
is the harmonic oscillation of surface electrons when the electromagnetic frequency (light) matches
that of the natural frequency of the electrons on the surface of the nanoparticles (Figure 1.4) [26,
29, 30]. It is this feature that facilitates the use of gold nanoparticles in photo thermal ablation,
radio-therapeutic dose enhancement, and molecular imaging among other applications. In a recent
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review by Curry et al. [31], gold nanoparticles have been shown as ideal contrast agents in
computed tomography while mediating photothermal therapy. Bisphosphonate functionalized gold
nanoparticles, in particular, have recently been shown to be useful for contrast-enhanced X-ray
detection of breast microcalcifications[32, 33].
1.5 Research Focus: Bisphosphonate Functionalized Gold Nanoparticles as a Potential
Treatment for Osteoporotic Disease
The use of nanoparticles for disease treatment is an increasingly popular area of research.
The potential for multi-functionality allows nanoparticles to be used as transport and delivery
vehicles for drugs and as diagnostic aides, among other applications, to address the unmet needs
of many such disease treatments. The overall goal of this doctoral research project is to study and
discuss the application of gold nanoparticle systems surface functionalized with primary amine
bisphosphonates, which is a classification of pharmaceuticals that is common in the treatment of
osteoporosis. Functionalized nanoparticles allow for greater intracellular concentrations of
pharmaceutical, while the properties of the gold nanoparticles may provide the ability to track the
pharmaceutical and enhance imaging. Below, we broadly describe the organization of this
dissertation to study the synthesis, characterization, and validation of bisphosphonate
functionalized gold nanoparticles as a potential treatment and means of study for osteoporotic
diseases.
Chapter 2 discusses the method for synthesis and functionalization of the colloidal gold
nanoparticles.

The research in this dissertation focuses on two different primary amine

bisphosphonates, alendronate and pamidronate, and their self-assembly on the nanoparticle
surface. The American Society of Clinical Oncology reports that the relative efficacy of
alendronate to pamidronate is 10:1, and interest lies in whether this trend remains intact when
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functionalized with GNP. It is important to note that efficacy is vaguely defined through multiple
factors, including bone density, bone markers, and skeletal event free survival. These
bisphosphonates were also chosen due to their common use as a benchmark for treatment in
osteoporosis. The choice of these two n-BPs also allows for study of the effect that chemical
structure might play on the formation of this nanoparticle system as they are very similar, but differ
by one carbon in their carbon backbone (Figure 1.5). Chapter 2 also discusses characterization of
the nanoparticles before and after functionalization through a suite of different techniques
including UV-vis spectroscopy, dynamic light scattering (particle sizing), tunneling electron
microscopy, and inductively coupled plasma mass spectrometry. These techniques provide insight
into the particle size and distribution as well as providing an estimate of the surface bound
bisphosphonate.
Chapter 3 discusses in vitro studies that were used to investigate the effect of these
bisphosphonate functionalized gold nanoparticles on cell viability and morphology. Two cell lines
were used for these studies: Raw 264.7 murine pre-osteoclasts and 7F2 murine osteoblasts. The
viability studies were done as mono cultures and co-cultures, as well as one study in the presence
of bone slices and assessed through the use of a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) viability assay. The morphology was assessed through fluorescence
microscopy in co-culture with the absence of bone. These studies provide insight into the effect of
these nanoparticle systems across a range of concentrations.
Chapter 4 describes the use of these nanoparticle systems in osteoclast and osteoblast in
vitro cell cultures, looking deeper into their effects on cell performance, such as key protein
expression and bone remodeling. Specifically we look into the effect of these nanoparticles on
osteoblast expression of RANKL and alkaline phosphatase. As discussed previously RANKL is a
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protein that plays a critical role in the bone remodeling process. Additionally, we look at how these
nanoparticles impact alkaline phosphatase expression in osteoblasts, as a marker of osteoblastic
differentiation and thus, an indicator of bone deposition[34]. Lastly, we discuss the effect of the
nanoparticles on bone deposition and bone resorption through calcium deposition assays along
with resorption assays and pit formation on bone slices. These final studies provide a more detailed
look at the effect of bisphosphonate functionalized gold nanoparticles on cell behavior and bone
remodeling.
Finally, Chapter 5 provides an overall summary of the results of this study on the effects
of this nanoparticle system as they pertain to these in vitro studies, and the discussion gives some
insights on future prospects and recommendations.
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Figure 1.1 Anatomy of bone.
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Figure 1.2 Osteoclast development and bone resorption.
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Figure 1.3 Osteoblast and osteoclast interaction.
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Figure 1.4 Localized surface plasmon resonance.
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Figure 1.5 Overview of the bisphosphonates used in this study.
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CHAPTER 2:
GOLD NANOPARTICLE SYNTHESIS AND CHARACTERIZATION 1
In this chapter, a detailed description is given on synthesis and characterization of
bisphosphonate functionalized gold nanoparticles. Our objective was to synthesize gold
nanoparticles with controlled size that is suitable for cellular uptake and functionalize the surface
using self-assembly by two different primary amine bisphosphonates. A host of characterization
techniques were used to assess the gold nanoparticle system and clarify the surface-modification.
Microscopy, spectroscopy, and scattering techniques were used to gain insight into the particle
size distribution, shape, and to help confirm surface modification with bisphosphonates.
Inductively coupled plasma mass spectrometry was used to ascertain the surface density of the
bisphosphonates on the gold nanoparticle surface.
2.1 Introduction
A means for localized delivery and in-vivo study of disease and treatment progression are
desirable features of any treatment methodology. Nanoparticles are colloidal systems in the
submicron size range that are stable when dispersed in solution[1]. Nanoparticles often have many
properties (electronic, catalytic, optical, and magnetic) that have made them an area of great
interest for applications such as catalysis and various medical therapies[2-5]. Gold nanoparticles,
for example, have been shown to be highly biocompatible, with low toxicity, in many studies [68]. Optimization of shape, surface functionality, and size has been investigated for promoting

1

Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K.
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B.
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optimal cellular uptake[9]. Gold nanoparticles have been investigated for use in drug delivery
applications for cancer treatment with promising results[10]. Additionally, they have shown
promising results as antimicrobial agents[6]. Gold nanoparticles possess an additional key feature
that makes them interesting for medical imaging and sensing applications. This feature is the
localized surface plasmon resonance (LSPR) that nanosized particles exhibit. LSPR is the
harmonic oscillation of surface electrons when the electromagnetic frequency (light) matches that
of the natural frequency of the electrons on the surface of the nanoparticles[10-12]. It is this feature
that is exploited for use in photo thermal ablation, radio-therapeutic dose enhancement, and
molecular imaging among many other applications.
2.2 Materials and Methods
2.2.1 Materials
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from
Sigma-Aldrich, St Louis, USA. Snakeskin dialysis membranes with a 10k MWCO were obtained
from SpectraPor. The optical absorption of the gold colloidal solutions were measured using a
Jasco V-530 spectrophotometer (Jasco, MD, USA). Dynamic light scattering (DLS) was
performed on a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK) equipped with
a red (633 nm) Helium-Neon laser. Transmission electron microscopy was done using a Morgagni
268D TEM microscope (FEI, OR, USA). TEM samples were prepared on Copper grid (200 mesh)
with Formvar/Carbon film from Electron Microscopy Sciences.
2.2.2 Gold Nanoparticle Synthesis and Functionalization
The gold nanoparticles were synthesized via an adaptation of the well-established Frens
method[13]. An aqueous solution of 110 ml of 1 mM HAuCl4 was reduced by 10 ml of 35 mM

18

citric acid while under refluxing conditions and continuous stirring.

The as-prepared gold

nanoparticle solution was stored in an amber glass bottle at 4°C.
The citrate-stabilized gold nanoparticles were surface modified by taking advantage of
what has been described as a coordination bond and partial electrostatic complex between primary
amine groups and the surface of gold[14, 15].

The primary amine group in nBP such as

alendronate and pamidronate can displace the citrate on the surface of the gold nanoparticles to
form a thin organic overlayer. Alendronate sodium trihydrate and pamidronate disodium salt
hydrate were obtained (Sigma-Aldrich, St Louis, USA) and used to prepare aqueous solutions of
1.1 mM concentration. Typically, 1 mL of the as-prepared stock solution of gold nanoparticles
was mixed with 0.8 mL of bisphosphonate stock solution and surface functionalization was
allowed to occur over 24 h at room temperature.
Excess bisphosphonate and citrate were removed by membrane dialysis using SpectraPor
Snakeskin dialysis membrane with a 10k MWCO. Dialysis was performed over 24 hours, using 1
L baths with bath changes at 2 and 10 hours.
2.2.3 UV-vis Spectrophotometry
The optical absorption of the gold colloidal solutions were measured using a Jasco V-530
spectrophotometer (Jasco, MD, USA). Before measurement, the sample of gold nanoparticle
solution was typically diluted by a factor of 20. The absorbance (A) at the plasmon absorption
maximum is linearly proportional to number density of particles (Np) by the relation [16, 17]:

A = ε ' LN p

(1)

where L is the path length of the optical cell (1 cm) and ε’ is the molar extinction coefficient.
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2.2.4 Dynamic Light Scattering
Dynamic light scattering (DLS) was performed on a Zetasizer Nano ZS90 (Malvern
Instruments, Worcestershire, UK) equipped with a red (633 nm) Helium-Neon laser. The scattered
light at 90° angle was recorded for a diluted colloidal solution (20X dilution) in a polystyrene
cuvette at 20°C. Two different samples and typically more than 10 measurement scans over a
duration of 60 seconds for each sample were averaged. The intensity size distribution from multimodal analysis of the correlation function (MNM algorithm) and the z-average diameter with
polydispersity index as per the cumulants analysis was determined.
2.2.5 Transmission Electron Microscopy
For particle sizing, transmission electron microscopy was done using a Morgagni 268D
TEM microscope (FEI, OR, USA). Samples were prepared by drying a diluted drop of citrate–
stabilized gold nanoparticle solution on a copper grid (200 mesh) with Formvar/Carbon film. The
TEM image was analyzed using ImageJ software [18] (NIH) and manual selection of particles to
determine a mean particle diameter.
2.2.6 Inductively Coupled Plasma – Mass Spectroscopy
Following literature reports [19, 20], Inductively Coupled Plasma Mass Spectrometry
(ICP-MS) was used to characterize the bisphosphonate functionalized GNP in this study. Samples
and calibration standards were analyzed with an Agilent 7500cx ICP-MS in no-gas mode.
Solutions were introduced into the ICP-MS with a MicroMist concentric nebulizer and a doublepass (Scott-type) quartz spray chamber and Peltier cooled to 20°C. Phosphorus was normalized
to scandium, while gold was normalized to indium. Following the recommendation in Allabashi
et al. [19], acidification with 1% HCl (v/v) was used. Samples were quantified using an external
calibration line composed of a blank and 5 standards in 1% HCl. The integration time was set at
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0.50 seconds for phosphorous and 0.10 seconds for Au, and the number of repetitions was set to
five. Each sample was run in triplicate. HCl blank solution (1%) was analyzed prior to each
standard and sample to monitor memory effects, although no correction was required. To estimate
bisphosphonate molecules per unit area of spherical nanoparticles the mass ratio (Rm) of
phosphorous to gold was determined for the functionalized gold nanoparticles. For particles with
a diameter D, the following relation was used for the surface density (σ) of alendronate or
pamidronate:

σ=

Rm
D
N Av ρ Au
2m p
6

(2)

where mP is the atomic weight of phosphorous, NAv is the Avogadro’s number, ρAu is the density
of bulk gold and the factor 2 accounts for two phosphorous atoms per bisphosphonate molecule.
2.2.7 Statistical Analysis
Statistical results are expressed as means +/- SD. Comparisons between data were made
with the use of student’s t-test where significance was determined at p ≤ 0.05.
2.3 Results and Discussion
Characterization of nanoparticle size typically requires more than one technique to obtain
an adequate picture of the size distribution[21]. Figure 2.1 shows a representative TEM image of
the gold nanoparticles and the size distribution obtained from TEM. Figure 2.2 provides the
intensity size distribution from DLS. The average size of the nanoparticles is approximately 15±3
nm (n=47) from TEM. The DLS results show a size distribution with a single peak that is centered
at 23±8 nm; the cumulants analysis gives z-average hydrodynamic diameter as 18 nm
(polydispersity index 0.26).
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While electron microscopy reflects the primary size of the particle, the statistical
representation of the distribution is poor due to small numbers and issues also exist from
aggregation or drying during sample preparation[21]. DLS on the other hand rapidly provides an
ensemble average with good statistical representation but provides hydrodynamic diameter of
particles and the intensity of scattered light is sensitive to the presence of small quantities of large
particles or clusters of smaller particles, which can skew the size distribution.

The results from

TEM and DLS in Figures 2.1 and 2.2 are in agreement with each other and suggest that the
nanoparticles population is 10-30 nanometers in diameter. The results in Figures 2.1 and 2.2 are
also consistent with the preparation method used here. Direct reduction of gold salt in the presence
of a stabilizer-reducer agent i.e. the well-established Frens method has been shown [13] to work
well in preparing particles with diameters up to 30 nm. The size range in Figure 2.1 is also
appropriate for cellular uptake through endocytosis[22]. Additionally, it is well accepted that
nanoparticle systems for in vivo use should remain below 100 nm in diameter to be most effective
in systemic delivery[9, 23].
Figure 2.3 shows the optical absorption characteristics of the gold nanoparticles systems.
The as-prepared GNP system has a plasmon absorbance maximum at a wavelength of 521 nm and
a plasmon bandwidth of approximately 60 nm. The absorbance peak near 521 nm is typical of
gold nanoparticles with average diameter in range of 15-25 nm[16, 24, 25]. This also leads to the
well-known red wine colored appearance of colloidal gold solutions of this size (Figure 2.4). The
plasmon bandwidth of 60 nm is also consistent with absence of significant numbers of small (<10
nm) or large (> 50 nm) sized nanoparticles (see Link and El-Sayed [16]), which is in agreement
with the DLS analysis shown in Figure 2.2.
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Results in Figure 2.3 reveal that the pamidronate and alendronate functionalized gold
nanoparticles exhibit maxima at 522 nm and 523 nm, respectively. No significant broadening of
the absorption peak post-functionalization is observed.

The slight red-shift in the case of

alendronate and pamidronate functionalized gold nanoparticle is congruent with the molecular size
of the bisphosphonates and expectation of a thin organic layer [26] on the surface of gold
nanoparticles and is also in agreement with past studies[27].
Using the optical absorbance for the gold nanoparticles at the plasmon maxima and the
molar extinction coefficient, Np can be estimated using equation 1. However, the effect of
nanoparticle size on ε’ is an important consideration in a polydisperse distribution. Link and ElSayed [16] have shown that the molar extinction coefficient (ε’) of the spherical gold nanoparticles
increases with increase in diameter of the nanoparticles. From their report, ε’ can change from
~8x107 M-1cm-1 for a diameter of 9 nm to ~1.3x109 M-1cm-1 for a diameter of 22 nm or ~2x1010
M-1cm-1 for a diameter of 48 nm. Here, a diameter of 15 nm, an interpolated ε’, and the absorbance
for as-prepared gold nanoparticle solutions gives the estimated Np as ~5x1012 particles/mL. Using
the quantity of gold salt used in the nanoparticle synthesis and assuming complete quantitative
reduction with no losses also yields a value for Np of ~5x1012 particles/mL, which agrees quite
well with the estimate from optical absorption.
Allabashi et al. [19] have shown recently that ICP-MS can be used for gold nanoparticle
characterization without a digestion step. Hinterworth et al. [20] have used the approach to
demonstrate quantification of ligand density for several thiol ligands on various sized gold
nanoparticles. Using similar procedures, the bisphosphonate functionalized nanoparticles (GP and
GA) were characterized by ICP-MS. Measurements show a phosphorous to gold mass ratio of
Rm= 0.0055 for GA and Rm=0.0014 for GP. ICP-MS quantification of the gold content in a sample
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of gold nanoparticles alone yields a value of ~194 ppm that on combination with the TEM results
gives an estimated nanoparticle concentration Np of ~6x1012 particles/mL, which is consistent with
the other estimates above.
The mass spectrometry results support the immobilization of nitrogen containing
bisphosphonates (nBP) on the surface of the gold nanoparticles. Additionally, by combining
equation 2 and the average diameter of 15 nm, ICP-MS measurements of the bisphosphonate
functionalized nanoparticles yield a surface density (σ) of approximately 0.65 molecules per nm2
(approximately 154 Å2/molecule) for GP and approximately 2.6 molecules per nm2 (approximately
39 Å2/molecule) for GA. The values for σ indicate a much less dense packing density than the 4.6
molecules per nm2 that is well-known for a strongly chemisorbed and well-ordered monolayer of
long chain n-alkanethiol molecules on planar gold surfaces with Au(111) crystallography[28, 29].
The nature of the bond [14, 15] between amines and the gold surface as well as the large
bisphosphonate head group possibly contribute to the lower packing density for pamidronate and
alendronate.
It is important to note that the above surface density values for GA and GP are estimates
given the polydispersity in size of the nanoparticles as well as factors such as non-spherical shape
of particles that impact other binding sites (edges and corners). An investigation directed on the
self-assembly of nBPs with controlled synthesis of nanoparticles with several sizes is necessary
for a well-defined value. Past literature on thiol-gold self-assembled monolayers shows that
shorter ligand chain lengths lead to lower surface density [30, 31] and the difference between
values for GP and GA is plausibly due to a similar effect from the shorter chain length of
pamidronate. In this context, a comparative surface study of gold nanoparticle functionalization
with pamidronate, alendronate, and neridronate can be useful.
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Figure 2.1 Size distribution of gold nanoparticles obtained from TEM. Inset shows a representative
TEM image with a 100 nm scale bar.
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Figure 2.2 Intensity size distribution from dynamic light scattering analysis from the gold
nanoparticle solution.
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Figure 2.3 UV-vis spectra of the gold nanoparticles before and after conjugation with
bisphosphonates. The spectra are marked as follows:  for gold nanoparticles alone;  for gold
nanoparticles conjugated with pamidronate;  for gold nanoparticles conjugated with alendronate.
Sparse markers have been used with one marker for every 15 data points.
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Figure 2.4 Image of the as-prepared gold nanoparticle stock solution.
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CHAPTER 3:
CELL VIABILITY AND MORPHOLOGY1
In this chapter, a detailed description is given on effects of bisphosphonate functionalized
gold nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. The
objective was to analyze the effect that modified nanoparticles had on cell viability and
morphology under different circumstances. The circumstances included mono-cultures of
osteoclasts and of osteoblasts as well as more physiologically relevant co-cultures that relied on
the RANKL expression of osteoblasts to differentiate the Raw 264.7 pre-osteoclast cells.
Colorimetric assays were used to quantify cell viability and fluorescence microscopy was used to
look at morphological changes in the cells’ structures.
3.1 Introduction
It is well established that aminobisphosphonates (n-BP) have a strong inhibitory effect on
osteoclasts, and are considered the strongest clinical inhibitors of bone resorption.
Bisphosphonates have been shown to reduce osteoclast viability, inhibit osteoclast recruitment,
inhibit osteoclasts-mediated resorption, reduce their ability to bind to bone, and disrupt
morphology[1]. Bisphosphonates were first used clinically to treat Paget’s disease[2]. Their
inhibitory effect works by inhibiting enzymes in the mevalonate pathway of cholesterol
synthesis[3]. This then leads to the reduction of levels of geranylgeranyl diphosphate. Since
geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)-

1

Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K.
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B.
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binding proteins that are necessary for osteoclast activity and survival [4, 5], this reduces the levels
of these binding proteins and compromises the viability of the cells. Finally, mature osteoclasts
resorb bone by excreting acid as well as cathepsin K from a ruffled cellular membrane border that
increases surface area to promote bone resorption. This dissolves the hydroxyapatite and fibrillar
collagen that are taken up through the cell membrane and continues to be digested on the way to
the secretory domain [6]. Any disruption to this the cell morphology may lead to an inability to
perform its normal functions.
Additionally, there have been studies that assert the positive effects of bisphosphonates on
osteoblast proliferation and bone nodule formation. Im et al. [7] showed that both alendronate and
risedronate increased cell count of both primary human trabecular bone and MG-63 osteoblastlike cells in vitro, with a maxima at about 10-8 M. Reinholz et al. [8] had the opposite effect with
starting concentrations of about 4x10-5 M. Results of a study by Schindeler et al. [9] show that
bound bisphosphonates have nearly no comparable effect on osteoblasts compared to osteoclasts
when they are cultured separately on phosphate coated quartz disks that were pretreated with
zoledronic acid. Their results showed that although osteoclasts were negatively influenced by this
substrate, osteoblasts were largely unaffected. Similar results were shown by Panzavolta et al.[10].
It has also been reported that at sufficiently low concentrations, bisphosphonates prevent apoptosis
by etoposide and corticosteroids in osteoblasts and osteocytes. This is done through connexin 43
channels and extracellular signal-regulated kinase (ERK) phosphorylation[11, 12].
However, there are numerous studies that present results of the negative effect of
bisphosphonates on osteoblast viability. A study by Orriss et al. [13] showed that zoledronate,
would reduce the number for osteoblast cells at concentrations equal to or greater than 100 nM.
Similar results were shown for pamidronate and clodronate, only at substantially higher
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concentrations of greater than or equal to 1 and 10 µM for pamidronate and clodronate
respectively. However, they did see generally positive effects on proliferation for concentrations
in the 1 nM to 1 µM range, with the exception of zoledronate. Idris et al. [14] show either no effect
or a slight positive effect on proliferation in the range of 100 nM or 1 µM (the lowest dose results
shown) when rabbit and mice osteoblasts were treated with pamidronate and alendronate in vitro.
The above discussion of past studies makes it apparent that though the conclusions of these
studies seem to differ, they also differ in the parameters of the studies. It is, therefore, important
whenever developing a new treatment to carefully consider all of these variables.
3.2 Materials and Methods
3.2.1 Materials
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from
Sigma-Aldrich, St Louis, USA. Gold nanoparticle solutions were prepared as discussed in Chapter
2. Raw 264.7 murine pre-osteoclast cells and 7F2 murine osteoblast cells were obtained from
ATCC. Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro, Mediatech, VA, USA) was
supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma). Viability was assessed using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) (Invitrogen) colorimetric assay. Absorbance for MTT assay was
read on a Synergy HT Microplate Reader from BioTek (Winooski, VT, USA). The rabbit antiactin primary antibody goat anti-rabbit IgG and DAPI were all obtained through Sigma-Aldrich,
St Louis, USA. Fluorescence microscopy images were captured using an EVOS FL Cell Imaging
System from Invitrogen.
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3.2.2 RANKL Differentiation of Raw 264.7 Pre-Osteoclast Cell Line
Murine pre-osteoclast cells (RAW 264.7) were recovered from cryogenic storage in 1×
DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum
(Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative
humidity. At approximately 80% confluence, the Raw 264.7 cells were cultured in media
supplemented with 50 ng/ml of recombinant mouse receptor activator of NF-κB ligand, or
RANKL, (R&D Systems, MN, USA) and allowed to incubate for eight days to encourage
differentiation into mature osteoclasts. This protocol was applied in all studies where osteoclast
cells were used unless otherwise noted.
3.2.3 Osteoclast Viability Study
RANKL-differentiated Raw 264.7 cells were seeded at a density of 4×103 cells/well in a
96-well plate. After allowing the cells to attach to the culture dish for 24 hours, the cells were
treated with the different variables as described.
A 72 h study was conducted with six groups, each done in triplicate, and designated as
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA),
cells treated with free pamidronate (P), and cells treated with free alendronate (A). Each treatment
was mixed with fresh medium before being added to the cells. The untreated cells (C) served as
the control.

For the free bisphosphonates, osteoclasts were treated with 1 to 5 μM of

bisphosphonates. These treatment concentrations are comparable to concentrations (1 nM -10 µM)
that have been used in other in vitro studies[15, 16]. In the case of samples treated with gold
nanoparticle systems, treatment with 10-50 μL of nanoparticle solution was used. In each case, the
50 μL volume i.e. the highest treatment concentration, corresponded to ~4x107 nanoparticles/cell.
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See Figure 3.1 for a schematic of the experimental design. A separate control was used for each
triplicate group so that the volume ratio of treatment to medium was maintained.
At the end of the 72 hour treatment period, the spent culture media was removed and 100
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was
added to all wells. The cells were then incubated at the previously described conditions for 4
hours. The purple formazan crystals were then dissolved with 100 µl of DMSO after removing the
media. After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630
nm[17]. A standard curve was produced through a similar procedure using untreated cells for each
cell line and all results were found to be within the range and linear region of the curve (Figure
3.3).
A separate study was conducted over 24 hours in order to assess the mechanism by which
the nanoparticles were internalized by the cells. This required a toxicity study to determine a safe
concentration of amiloride. Cells were treated with 10 serial dilutions of amiloride, with a
maximum concentration of 40 µg/mL over a 24 hour period. This time period was chosen because
of the relatively high toxicity of amiloride, in an attempt to minimize its effect. Following this
study, a similar viability study to the one described previously, was done using two different
amiloride treatments. The cells were pretreated for 1 hour with 0 µg/mL, 1.25 µg/mL or 10 µg/mL
of amiloride and then the same treatments noted above were added without the removal of the
amiloride. At the end of the 24 hour period, the viability was assessed through MTT.
3.2.4 Osteoblast Viability Study
Murine osteoblast cells (7F2) were recovered from cryogenic storage in 1× DMEM
(Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and
1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative humidity. Cell
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viability was assessed 72 hours after treatment with a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) (Invitrogen) colorimetric assay. Subsequently, the osteoblasts were
seeded at a density of 2×103 cells/well in a 96-well plate. The difference in seed count from the
previously described osteoclasts viability study was due to size difference of the cells and concern
about overcrowding. After allowing the cells to attach to the culture dish for 24 hours, the cells
were treated with different variables as described.
A 72 h study was conducted with six groups, each done in triplicate, and designated as
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA),
cells treated with free pamidronate (P), and cells treated with free alendronate (A). Each treatment
was mixed with fresh medium before being added to the cells. The untreated cells (C) served as
the control. For the free bisphosphonates, osteoblasts were treated with 0.5 to 2.5 μM of
bisphosphonates as one-half the seeding density was used compared to the previously discussed
osteoclast study. These treatment concentrations are comparable to concentrations (1 nM -10 µM)
that have been used in other in vitro studies[15, 16]. In the case of samples treated with gold
nanoparticle systems, treatment with 10-50 μL of nanoparticle solution was used. In each case, the
50 μL volume i.e. the highest treatment concentration, corresponded to ~4x107 nanoparticles/cell.
See Figure 3.5 for a schematic of the experimental design. A separate control was used for each
triplicate group so that the volume ratio of treatment to medium was maintained.
At the end of the 72 hour treatment period, the spent culture media was removed and 100
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was
added to all wells. The cells were then incubated at the previously described conditions for 2. The
purple formazan crystals were then dissolved with 100 µl of DMSO after removing the media.
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After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630 nm[17].
A standard curve was produced through a similar procedure using untreated cells for each cell line
and all results were found to be within the range and linear region of the curve (Figure 3.7).
3.2.5 Co-Cultured Viability Study
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75%
relative humidity. Subsequently, the undifferentiated Raw 264.7 cells and the osteoblasts were
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in
96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect
physiologically relevant conditions. These seeding densities allow for comparable particle/cell
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the
culture dish for 24 hours, the cells were treated with different variables as described below.
A 72 h study was conducted with six groups, each done in triplicate, and designated as
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with
pamidronate functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA),
cells treated with free pamidronate (P), and cells treated with free alendronate (A). Each treatment
was mixed with fresh medium before being added to the cells. The untreated cells (C) served as
the control. For the free bisphosphonates, the cells were treated with 1 to 5 μM of bisphosphonates.
These treatment concentrations are comparable to concentrations (1 nM -10 µM) that have been
used in other in vitro studies[15, 16]. In the case of samples treated with gold nanoparticle systems,
treatment with 10-50 µL of nanoparticle solution was used. In each case, the 50 µL volume i.e. the
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highest treatment concentration, corresponded to ~2.7x107 nanoparticles/cell. A separate control
was used for each triplicate group so that the volume ratio of treatment to medium was maintained.
At the end of the 72 hour treatment period, the spent culture media was removed and 100
µl of fresh culture media supplemented with MTT powder at a concentration of 5 mg/ml, was
added to all wells. The cells were then incubated at the previously described conditions for 2. The
purple formazan crystals were then dissolved with 100 µl of DMSO after removing the media.
After 30 minutes on a rocker, absorbance was read at 540 nm with a reference filter at 630 nm[17].
See Figure 3.8 for a schematic of the experimental design. A standard curve was produced through
a similar procedure using untreated cells for each cell line and all results were found to be within
the range and linear region of the curve (Figure 3.10).
3.2.6 Morphology via Fluorescence Microscopy
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75%
relative humidity. Subsequently, the undifferentiated Raw 264.7 cells and the osteoblasts were
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in
96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect
physiologically relevant conditions. These seeding densities allow for comparable particle/cell
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the
culture dish for 24 hours, the cells were treated with different variables as described below.
Fluorescence imaging was done 72 h after treatment with six groups designated as follows:
untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with pamidronate
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functionalized GNP (GP), cells treated with alendronate functionalized GNP (GA), cells treated
with free pamidronate (P), and cells treated with free alendronate (A). Each treatment was mixed
with fresh medium before being added to the cells. The untreated cells (C) served as the control.
For the free bisphosphonates, the cells were treated with 3 μM of bisphosphonates. These treatment
concentrations are comparable to concentrations (1 nM -10 µM) that have been used in other in
vitro studies[15, 16]. In the case of samples treated with gold nanoparticle systems, treatment with
30 µL of nanoparticle solution was used corresponded to ~1.6x107 nanoparticles/cell.
At the end of the 72 hour treatment period, the spent culture media was removed and the
cells were rinsed with 1x PBS. The cells were then fixed with 4% p-Formaldehyde at room
temperature for 10 minutes. After rinsing with 1x PBS, a permeabilization step was performed by
treating the cells with 0.1% Triton X100 in 1x PBS for 5 minutes. The rabbit anti-actin (1:1000 in
3% BSA, Sigma) primary antibody was then added to each well and incubated for 1 hour at room
temperature. After rinsing with 0.1% Triton X100 in 1x PBS the goat anti-rabbit IgG (1:500, 3%
BSA, Sigma) secondary antibody was added and allowed to incubate at room temperature for 1
hour. After rinsing again with 0.1% Triton X100 in 1x PBS, DAPI nuclear stain (300 nM in 0.1%
Triton X100, Sigma) was added to each well for 10 minutes at room temperature before rinsing
with 1x PBS. The samples were then imaged using an EVOS FL Cell Imaging System from
Invitrogen (DAPI excites at 357 nm with emissions at 447 nm and FITC excites at 470 nm with
emissions at 525 nm).
3.2.7 Statistical Analysis
Statistical results are expressed as means +/- SD. Comparisons between data were made
with the use of student’s t-test where significance was determined at p ≤ 0.05.
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3.3 Results and Discussion
3.3.1 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Osteoclast
Viability
Figure 3.2 compares results from treatment of osteoclast (Raw 264.7 cell line, 4000
cell/well) samples with increasing concentration of bisphosphonates. In Figure 3.2A, treatment
with free bisphosphonates shows a lack of significant differences compared to the controls over
the entire concentration range. In Figures 3.2B and 3.2C, the gold nanoparticles alone (sample G)
has no effect on osteoclast viability in all but the highest treatment concentration where a
statistically significant decrease in osteoclast cell viability compared to the controls is observed.
Most importantly, Figures 3.2B and 3.2C show that when the osteoclasts are treated with
pamidronate and alendronate conjugated to gold nanoparticles (GP and GA, respectively), there is
a significant decrease in cell viability above 40% treatment, which corresponds to ~6x1010
functionalized particles or ~0.3 µM for pamidronate and ~1 µM for alendronate using the estimate
of surface density (σ) noted in Chapter 2.
The lack of significant decrease in OC viability upon treatments by pamidronate or
alendronate in their free form (Figure 3.2A) agree with the report by Martins et al. [15] wherein
differentiated Raw 264.7 cells showed a decrease in cell viability only when treated with a
concentration of 10 µM or larger of alendronate. Additionally, Tsubaki et al. [16] reported a
decrease in cell viability at 5 µM of alendronate and above, though they used the C7 osteoclast
cell line, which suggests that the threshold is sensitive to the cell line. The lack of significant
decrease in OC viability upon treatment with gold nanoparticles alone indicates that GNPs likely
have no significant effects on the viability of these cell lines when they are not conjugated with
BPs and this result is in agreement with what is typically reported in literature about the low
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toxicity of GNPs on mammalian cells[18-20]. The one exception to the above is the decrease in
viability for osteoclasts at the 100% treatment in Figure 3.2B and 3.2C. This likely represents a
slight cytotoxic effect of the gold nanoparticles on this particular cell line at the highest
nanoparticle per cell concentration (approximately 4x107 nanoparticles/cell).
A primary goal of this study was to determine the effect of delivering bisphosphonate
bound to gold nanoparticles rather than in its free form. It is well known that amine-containing
bisphosphonates have a strong inhibitory effect on osteoclasts, and are considered the strongest
clinical inhibitors of bone resorption. Bisphosphonates were first used clinically to treat Paget’s
disease [2] and their inhibitory effect works by inhibiting enzymes in the mevalonate pathway of
cholesterol synthesis[3]. This then leads to the reduction of levels of geranylgeranyl diphosphate.
Since geranylgeranyl diphosphate is required for the prenylation of guanosine triphosphate (GTP)binding proteins, which are necessary for osteoclast activity and survival [4, 5], this reduces the
levels of these binding proteins, thus compromising the viability of the cells. The comparison in
Figure 3.2 shows that attaching the bisphosphonates to the surface of the nanoparticles leads to
increased apoptotic effects of the bisphosphonates on the OC cells. This can likely be attributed to
the fact that OC cells are predominantly endocytotic in nature and have been shown to readily
internalize GNP through endocytosis[21, 22]. With OC cells normally internalizing by means of
endocytosis, not much free BP would normally be taken up, as there is nothing about the small
molecule that should activate an endocytosis or micropinocytosis pathway. This leaves only
diffusive and membrane protein channel mediated uptake of the free drug. However, GNP is
readily internalized and with each particle approximately 102-103 molecules of surface attached
BP are carried into the cell. The greater intercellular concentration of the bisphosphonates, is,
plausibly, the reason for the lower cell viability. Similar phenomenon has also been noted in the
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literature by Champion et al. in their study of detailing increased enzymatic activity upon higher
particle uptake in cells[23, 24]. A study was attempted in the interest of investigating this
hypothesis.
Since these gold nanoparticle systems do not possess any signaling moieties that would
trigger specific uptake into the cell, the likely mode of uptake is macropinocytosis[25].
Macropinocytosis is a regulated form of endocytosis that mediates the non-selective uptake of
various extracellular components and it is a highly active feature of macrophage related cell types
[25] like osteoclasts. Amiloride is a well-known inhibitor of the macropinocytic pathway and acts
by inhibiting the Na+/H+ exchanger pump in the plasma membrane[26, 27]. The intent was to
block macropinocytosis via treatment with amiloride, and then compare viability results of
amiloride blocked and unblocked cells when treated with functionalized gold nanoparticles. By
blocking the likely pathway for uptake of these gold nanoparticles, we should see a decreased
effect on cell viability. First, it was necessary to determine a safe concentration of amiloride for
this cell line, as it has been shown to be relatively toxic. Figure 3.4 shows the results of the toxicity
study. There appears to be a plateau (at ~10 µg/mL) in the viability as the concentration of
amiloride decreases. Note that with the exceptions of the 5, 2.5, and 1.25 µg/mL treatments, all
treatments showed significant decreases in viability, even at lower concentrations. We chose to
move forward with two different amiloride concentrations, 10 and 1.25 µg/mL. Unfortunately, the
study was inconclusive. Every attempt showed either no decrease in viability that should coincide
with previous studies, or all amiloride treatments further decreased cell viability beyond that of
the normal treatments. Further study into the internalization mechanism would be useful in further
development of nanoparticle based treatments.
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3.3.2 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Osteoblast
Viability
Figure 3.6 compares samples of osteoblast (7F2 cell line, 2000 cells/well) treated with
similar increasing concentration. In case of treatment with free bisphosphonates, Figure 3.6A
shows no effect of treatment on osteoblasts at all but the highest concentration of free alendronate.
Figures 3.6B and 3.6C show that gold nanoparticles alone (G) have no effect on osteoblast viability
at all treatments. In case of treatments with functionalized nanoparticles, only at sufficiently high
variable concentration there are significant differences compared to the controls. Figure 3.6B
shows osteoblast viability is significantly decreased compared to the controls beyond 60%
treatment for GP, which corresponds to ~5x1010 functionalized particles or ~0.2 µM for
pamidronate using the estimate of surface density (σ). Figure 3.6C shows lack of significant
decrease in osteoblast viability at all but the highest variable concentration of 100% for GA, which
corresponds to approximately 0.8x1011 functionalized particles or ~1.5 µM for alendronate using
the estimate of surface density (σ).
It is also necessary to elucidate the effects of GP and GA on OB viability compared to the
free forms of the bisphosphonates. The validity of this mode of treatment hinges on the ability to
shift the balance from bone resorption in the direction of bone formation. In order to leverage
viability as a means of shifting the balance, it is necessary to decrease the viability of the OC cells
while having no significant effect on OB cell viability. As can be seen in Figure 3.6, there is no
decrease in OB viability with increasing concentration of free bisphosphonates until the 2.5 µM
free alendronate treatment. In case of the functionalized nanoparticles, a significant decrease
compared to controls is observed when treatment concentration reaches ~0.5x1011 particles for GP
(~0.2 µM pamidronate) and ~0.8x1011 particles for GA (~1.5 µM alendronate). These results are
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in general agreement with what is reported in the literature, where BP, at sufficiently low
concentrations, have been shown to prevent apoptosis by etoposide and corticosteroids in
osteoblasts and osteocytes[9, 10]. These viability results provide insight into the optimization of
potential treatment concentrations.
3.3.3 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Co-Culture
Viability
Figure 3.9 compares results from treatment of osteoclast (Raw 264.7 cell line, 4000
cell/well) and osteoblast (7F2 cell line, 2000 cells/well) co-culture samples with increasing
concentration of bisphosphonates. In Figure 3.9A, treatment with free bisphosphonates shows a
lack of significant differences compared to the controls over the entire concentration range with
the one exception of the 60% (3 µM) pamidronate.

In Figures 3.9B and 3.9C, the gold

nanoparticles alone (sample G) shows a statistically significant decrease in cell viability for the
40% and 60% treatments compared to the controls, which corresponds to ~6x1010 and ~1x1011
particles respectively. However, Figures 3.9B and 3.9C also shows that when the cells are treated
with pamidronate and alendronate conjugated to gold nanoparticles (GP and GA, respectively),
there is a significant decrease, compared to controls, in cell viability starting at 40% treatment and
increasing with concentration. This corresponds to a concentration range of ~6x1010 to ~1.6 x1011
functionalized particles or ~0.3 µM to ~0.8 µM for pamidronate and ~0.6 µM to ~1.6 µM for
alendronate. Most importantly, these same treatments are all statistically significant decreases
when compared to gold nanoparticles alone in all but the highest concentration of pamidronate
functionalized gold nanoparticles. The estimate of surface density (σ) noted in Chapter 2 was again
used to establish these values.
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As discussed previously, OC and OB cells work closely together to keep the bone
remodeling process in check. Osteoclast formation through differentiation into multinucleated
mature osteoclasts are formed by fusion of circulating precursor hematopoietic cells [28] and
require cell-to-cell interaction between said precursor’s and osteoblasts[29].

This interplay

between these cells is extremely important in maintaining balance, so it is important to consider
the effects of GP and GA versus the free bisphosphonates on a more physiologically relevant coculture. As can be seen in Figure 3.9A, there is no decrease in overall viability with increasing
concentration of free bisphosphonates with the one exception of 3 µM free pamidronate treatment.
Figure 3.9B and 3.9C show an apparent toxicity to GNP alone with a threshold at ~6x1010 particles.
Although the approximate nanoparticle per cell concentration remained similar between this coculture study and the previously discussed mono-culture studies, the total nanoparticle and surface
bound bisphosphonate concentrations were twice the total concentration in the osteoblast viability
study. This greater available quantity of GNP may have led to the apparent toxicity, as there is no
way to separate the viability data of the two cell lines in this co-culture study. Although GNPs
have been reported as having low cytotoxicity to various cell lines [19, 30], the concentration of
GNP used in these studies are orders of magnitude greater and may be encroaching on the toxicity
limit of these cells. Furthermore, as a limit to in vitro studies, we cannot reproduce the ability of
an in vivo system to clear nanoparticles from the body through the renal system for example[31].
Repeated dosing is difficult in vitro as the gold nanoparticle concentrations would continue to rise
with every does and compound the cytotoxic effects. With an in vivo system’s ability to clear the
nanoparticles over time, a dosing regimen is more viable. In the case of the functionalized
nanoparticles, a significant decrease compared to controls and GNP alone is observed when the
treatment concentration reaches ~6x1010 functionalized particles and decreases further with
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increasing treatment concentration to ~1.6 x1011 functionalized particles. These values correspond
to ~0.3 µM to ~0.8 µM for pamidronate and ~0.6 µM to ~1.6 µM for alendronate bound to the
surface based on the estimate of surface density (σ) discussed in chapter 2. These results are in line
with the previously discussed mono-culture studies, where we see an increased effect on cell
viability at significantly lower concentrations of bisphosphonates. This is likely in part due to the
fact discussed previously, that OC cells are predominantly endocytotic in nature and have been
shown to readily internalize GNP through endocytosis[21, 22]. These viability results bring to light
a number of potential considerations into the optimization of potential treatments, such as dosing
and in vitro versus in vivo.
3.3.4 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Cell
Morphology in Co-Culture
Figure 3.11 shows representative fluorescence microscopy images of osteoclast (Raw 264.7
cell line, 4000 cell/well) and osteoblast (7F2 cell line, 2000 cells/well) co-culture samples across
multiple treatments corresponding to the 60% treatment variables from the co-culture viability
study. Cytoskeletal actin is represented in green (FITC) and nuclei are represented in blue (DAPI).
Multinucleated osteoclast cells are present in all samples. The arrow in Figures 3.11C, which
corresponds to cells treated with which corresponds to ~1x1011 functionalized particles or ~0.5 µM
for pamidronate, indicates a multinucleated osteoclast with disrupted nuclear morphology. Figure
3.12 shows a representation of the different between healthy and unhealthy cells. This sample was
the only sample where evidence of this disrupted morphology was present. No clear evidence of
disrupted actin morphology was present in any of the samples.
Osteoclasts can generally be distinguished from other bone cells by their large size and
multiple nuclei [32] as seen in Figure 3.11. Figure 3.11 also shows smaller cells with single nuclei,
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which are undifferentiated precursor cells. The presence of the mature osteoclasts supports the
reasoning behind the use of a physiological co-culture, as the osteoblasts were the sole source of
the RANKL that lead to the differentiation of the osteoclasts[33, 34]. Figure 3.11C shows a mature
osteoclast with disrupted nucleus morphology (indicated by the arrow) and is similar to the results
of study by Nicolin et al.[35]. This malformation is represented by the kidney bean shape to the
nuclei rather than the typically circular or ellipsoidal shape present in healthy cells. All other
treatments showed healthy cell morphology (indicated by arrows in all other images), being
circular or ellipsoidal in shape. As nuclei of healthy cells are involved in protein synthesis among
many other functions, disrupted morphology indicates compromised cell function. These results
are consistent with what has been reported previously about bisphosphonates disrupting
morphology[1] and point out an additional means of modulating bone resorption rather than just
through viability.
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Figure 3.1 Schematic of experimental setup for osteoclast viability study.
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Figure 3.2 Effect of various treatments on osteoclast (Raw 264.7) viability after 72 hours. (A: top)
Treatment with free pamidronate (P) and alendronate (A) compared with control (C). Here 100%
treatment corresponds to 5 μM. (B: middle) Treatment with gold nanoparticles alone (G) and
pamidronate functionalized nanoparticles (GP) compared with control (C). Here 100% treatment
corresponds to ∼1.6 × 1011 particles and ∼0.8 μM pamidronate. (C: bottom) Treatment with gold

nanoparticles alone (G) and alendronate functionalized nanoparticles (GA) compared with control
(C). Here 100% treatment corresponds to ∼1.6 × 1011 particles and ∼3 μM alendronate. Asterisk
denotes a significant difference P ≤0.05 relative to control.
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Figure 3.3 Calibration curve for osteoclast viability study.
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Figure 3.4 Effect of amiloride on osteoclast (Raw 264.7) viability after 24 hours. Amiloride
toxicity on osteoclasts was assessed across ten serial dilutions of amiloride, with a maximum
concentration of 40 µg/mL. Asterisk denotes a significant difference P ≤0.05 relative to the
untreated control (C).

55

C 20%

C 20%

C 20%

GP 40%

GP 40%

GP 40%

P 60%

P 60%

P 60%

Empty

Empty

Empty

G 20%

G 20%

G 20%

GA 40%

GA 40%

GA 40%

A 60%

A 60%

A 60%

Empty

Empty

Empty
Empty

GP 20%

GP 20%

GP 20%

P 40%

P 40%

P 40%

C 100%

C 100%

C 100%

Empty

Empty

GA 20%

GA 20%

GA 20%

A 40%

A 40%

A 40%

G 100%

G 100%

G 100%

Empty

Empty

Empty

P 20%

P 20%

P 20%

C 60%

C 60%

C 60%

GP 100% GP 100% GP 100%

Empty

Empty

Empty

GA 100% GA 100% GA 100%

A 20%

A 20%

A 20%

G 60%

G 60%

G 60%

Empty

Empty

Empty

C 40%

C 40%

C 40%

GP 60%

GP 60%

GP 60%

P 100%

P 100%

P 100%

Empty

Empty

Empty

G 40%

G 40%

G 40%

GA 60%

GA 60%

GA 60%

A 100%

A 100%

A 100%

Empty

Empty

Empty

Figure 3.5 Schematic of experimental setup for osteoblast viability study.

56

Figure 3.6 Effect of various treatments on osteoblast (7F2) viability after 72 hours. (A: top)
Treatment with free pamidronate (P) and alendronate (A) compared with control (C). Here 100%
treatment corresponds to 2.5 μM. (B: middle) Treatment with gold nanoparticles alone (G) and
pamidronate functionalized nanoparticles (GP) compared with control (C). Here 100% treatment
corresponds to ∼0.8 × 1011 particles and ∼0.4 μM pamidronate. (C: bottom) Treatment with gold

nanoparticles alone (G) and alendronate functionalized nanoparticles (GA) compared with control
(C). Here 100% treatment corresponds to ∼0.8 × 1011 particles and ∼1.5 μM alendronate. Asterisk
denotes a significant difference P ≤ 0.05 relative to control.
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Figure 3.7 Calibration curve for osteoblast viability study.
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Figure 3.8 Schematic of experimental setup for co-culture viability study.
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Figure 3.9 Effect of various treatments on osteoclast (Raw 264.7) and osteoblast (7F2) co-culture
viability after 72 hours. (A: top) Treatment with free pamidronate (P) and alendronate (A)
compared with control (C). Here 100% treatment corresponds to 5 μM. (B: middle) Treatment
with gold nanoparticles alone (G) and pamidronate functionalized nanoparticles (GP) compared
with control (C). Here 100% treatment corresponds to ∼1.6 × 1011 particles and ∼0.8 μM

pamidronate. (C: bottom) Treatment with gold nanoparticles alone (G) and alendronate
functionalized nanoparticles (GA) compared with control (C). Here 100% treatment corresponds
to ∼1.6 × 1011 particles and ∼3 μM alendronate. Asterisk denotes a significant difference P ≤0.05
relative to control. Pound sign denotes a significant difference P ≤0.05 between pairs.
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Figure 3.10 Calibration curve for co-culture viability study.
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Figure 3.11 Effect of various treatments on the morphology of osteoclast (Raw 264.7) cells in coculture after 72 hours. Treatments are noted as follows: control (A), gold nanoparticles alone (B),
pamidronate functionalized nanoparticles (C), alendronate functionalized nanoparticles (D), free
pamidronate (E), and free alendronate (F). Free bisphosphonate treatment concentrations were 3
μM. All gold nanoparticle treatments corresponded to ∼1 × 1011 particles while the resulting
concentration due to functionalized bisphosphonates corresponded to ∼0.48 μM pamidronate and
∼1.8 μM alendronate. Arrows indicate osteoclast nuclei of interest and scale bar = 100 μm.
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Figure 3.12 Schematic comparing difference in cell morphology of osteoclasts.
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CHAPTER 4:
CELL BEHAVIOR AND ACTIVITY1
In this chapter, a detailed description is given on effects of bisphosphonate functionalized
gold nanoparticles on important behavior and activity of osteoclast and osteoblast cells in vitro.
The objective was to analyze the effect that functionalized nanoparticles have on expression of
key proteins and enzymes in the osteoclast-osteoblast interplay. Additionally, the effect of surfacemodified nanoparticles on mineral deposition and bone resorption performance is also detailed. A
number of different techniques were used to quantify RANKL and alkaline phosphatase expression
in osteoblasts, as well as calcium deposition. Various staining and imaging techniques were used
to observe calcium nodule formation and resorption pits in bovine bone slices.
4.1 Introduction
Amino-bisphosphonates (n-BP) are considered the strongest clinical inhibitors of bone
resorption, through their inhibition of hydroxyapatite breakdown[1, 2]. Various oral and IV
bisphosphonates are FDA-approved for the treatment of many bone remodeling diseases, including
osteoporosis, Paget disease, and Legg-Calve-Perthes[3-6]. Bisphosphonate therapy is the
treatment of choice in osteoporosis, which is by far the most common clinical condition in which
it is used. Increased risk of fracture is a hallmark of osteoporosis due to compromised bone strength
and density. Paget disease of bone involves disordered bone remodeling, resulting from an

1

Part of this chapter was published in Conners, Christopher M., Bhethanabotla, Venkat R., and Gupta, Vinay K.
(2015). "Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on
osteoclast and osteoblast viability." J Biomed Mater Res B. Permission is included in Appendix B.
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imbalance in osteoclast-mediated bone resorption and osteoblast-mediated bone deposition[7].
This often results in pain, fractures, and serious deformity. The application of bisphosphonate
therapy leads to suppression of the accelerated bone resorption, which is considered the underlying
cause of the disease.
Another consideration is the potential effect of bisphosphonates on osteoblasts. Osteoblasts
express proteins that have been shown to be another major factor in the remodeling process of
bone. Osteoblasts express receptor activator of nuclear factor (NF)-κB ligand (RANKL) as well as
osteoprotegerin (OPG) that along with RANK, RANKL’s receptor expressed on OC cells, play a
critical role in these three processes. RANKL binds with RANK expressed on the surface of preosteoclast cells that promotes osteoclastogenesis[8]. OPG, expressed on the surface of osteoblasts,
is a competitor protein to RANK that binds RANKL and helps to modulate this recruitment and
differentiation process[9]. Modulation of the balance between the expression of OPG or RANKL,
would therefore lead to modulation of osteoclastogenesis.
Furthermore, the exact effect of bisphosphonates on osteoblasts is not well agreed upon. In
the context of bone formation, Orriss et al [10] performed a study where they tested the direct
effect of unbound zoledronate, pamidronate and clodronate on primary rat osteoblast cells. They
showed that with continuous treatment at concentrations as low as 10 nM, zoledronate was able to
reduce bone mineralization. They also looked at the effect of zoledronate on osteoblasts cultured
on dentine. Similar effects were seen, but at concentrations that were 10 to 100 fold greater. Idris
et al. [11] saw similar results in their study, where they showed an inhibition of bone nodule
formation at concentrations of 500 nM-1 µM for two bisphosphonates, namely pamidronate and
alendronate. However, no inhibition for these concentrations was seen for etidronate and
clodronate. Additionally, ALP and cell numbers were unaffected by any of these bisphosphonates
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and at any of these concentrations. Idris et al. concluded that these results raise concern since these
bisphosphonates caused osteoblast apoptosis as well as inhibited protein prenylation in a dose
dependent manner in the range for 20-100 µM. A different study by Knoch et al. [12] looked at
the effect of bisphosphonates on bone marrow stromal cells (BMSC). BMSC are pluripotent cells
that can differentiate into osteoblasts, adipocytes, fibroblasts and myocytes[13]. BMSC were
acquire from patients undergoing total hip replacement therapy and cultured for use in their in vitro
study. Their results showed an increase in proliferation of BMSC as well initiation toward
osteoblastic differentiation when subjected to alendronate, risedronate and zoledronate, in a dose
and time dependent manner.
Therefore, it is obvious that great consideration needs to be given to the concentrations that
osteoblasts are subjected to in vivo and to the concentrations used when performing in vitro studies.
4.2 Materials and Methods
4.2.1 Materials
Alendronate sodium trihydrate and pamidronate disodium salt hydrate were obtained from
Sigma-Aldrich, St Louis, USA. Gold nanoparticle solutions were prepared as discussed in Chapter
2. Raw 264.7 murine pre-osteoclast cells and 7F2 murine osteoblast cells were obtained from
ATCC. Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro, Mediatech, VA, USA) was
supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma). Goat anti-mouse TRANCE/RANK L/TNFSF11, HRP-conjugated anti-goat
secondary antibody, and recombinant mouse receptor activator of NF-κB ligand (RANKL) were
obtained through R&D Systems (MN, USA). A Calcium Colorimetric Assay kit and an Alkaline
Phosphatase Diethanolamine Activity Kit were obtained from Sigma as well. Protein bands were
detected using chemiluminescence (LumiGLO; Cell Signaling) and imaged using a FluorChem E
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System (ProteinSimple). Protein bands were quantified using image analysis software
(AlphaView; ProteinSimple). All absorbance assays were read on a Synergy HT Microplate
Reader from BioTek (Winooski, VT, USA).
4.2.2 RANKL Differentiation of Raw 264.7 Pre-Osteoclast Cell Line
Murine pre-osteoclast cells (RAW 264.7) were recovered from cryogenic storage in 1×
DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum
(Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative
humidity. At approximately 80% confluence, the Raw 264.7 cells were cultured in media
supplemented with 50 ng/ml of recombinant mouse receptor activator of NF-κB ligand, or
RANKL, (R&D Systems, MN, USA) and allowed to incubate for eight days to encourage
differentiation into mature osteoclasts. This protocol was applied in all studies where osteoclast
cells were used unless otherwise noted.
4.2.3 Western Blot for RANKL Expression
The protein expression study was done in duplicate on the six groups noted above at a
single treatment concentration. Murine osteoblast cells (7F2) were recovered from cryogenic
storage in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal
bovine serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and
75% relative humidity. After allowing the cells to attach to the culture dish for 24 hours and
subsequent treatment for 24 hours. The treatment concentrations were as follows: 1.5 µM for free
pamidronate (P) and alendronate (A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2
µM for pamidronate (GP) and 0.9 µM alendronate (GA). The cells were then washed once with
1x PBS and lysed using an SDS based lysis buffer supplemented with DTT and halt protease and
phosphatase inhibitors. A total cell lysate (106 cells/mL) was sonicated to decrease viscosity,
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heated at 95°C for 5 min and cooled on ice for 10 min. After centrifugation at 13,000 rpm for 1.5
min, the lysates were separated using a 4%–12% Bis-Tris gel (1 hour at 150 V) and transferred to
nitrocellulose membrane via an electrophoretic cell (1 hour at 350 mA).
Membranes were blocked with blocking buffer containing 5% (wt/vol) nonfat dry milk in
TBST on a rocker platform for 1 hour at room temperature. Membranes were incubated with goat
anti-mouse TRANCE/RANK L/TNFSF11 (0.25 ng/mL in 5% milk, R&D Systems) overnight at
48°C. After being washed three times with TBST for 5 min each, the membranes were incubated
with HRP-conjugated anti-goat (1:5,000 dilution in 5% nonfat dry milk, 1 hour at room
temperature; R&D Systems). After being washed three times again, the protein bands were
detected using chemiluminescence (LumiGLO; Cell Signaling) as per manufacturer’s instructions
and imaged using a FluorChem E System (ProteinSimple). For loading control, the membranes
were stripped using a stripping buffer (Thermo Scientific) for 30 min at room temperature and
probed again for β-actin (Cell Signaling). Protein bands were quantified by densitometry using
image analysis software (AlphaView; ProteinSimple) and were normalized to the intensity of βactin.
4.2.4 Alkaline Phosphatase Expression
Murine osteoblast cells (7F2) were recovered in 1× DMEM (Cellgro, Mediatech, VA,
USA) supplemented with 10% (vol/vol) fetal bovine serum (Sigma) and 1% (vol/vol) antibiotic–
antimycotic (Sigma) at 37 ºC, 5% CO2 and 75% relative humidity. The osteoblasts were then
seeded at a density of 3.2×104 cells/well in a 96-well plate. After allowing the cells to attach to the
culture dish for 24 hours, the cells were treated with different variables as described below.
A 7 day study was conducted with six groups, each done in duplicate, and designated as
follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells treated with
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pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P). Each treatment
was mixed with fresh medium before being added to the cells. The untreated cells (C) served as
the control. The treatment concentrations for the experiment were as follows: 1 µM for free
pamidronate (P) and alendronate (A); ~0.3x1011 particles for G, GP, and GA, that is, ~0.2 µM for
functionalized pamidronate (GP) and ~0.6 µM for functionalized alendronate (GA). In the case of
samples treated with gold nanoparticle systems, treatment with 10 μL of nanoparticle solution was
used. These concentrations correspond to the toxicity thresholds that resulted from earlier viability
studies discussed in Chapter 3. By staying at or below the toxicity threshold, we expect to remove
viability as a variable. A separate control was used for each group so that the volume ratio of
treatment to medium was maintained.
At the end of the treatment period, the spent culture media was removed and the cells were
rinsed with 1x PBS. The cells were then lysed with 50 µL of DI water through a freeze/thaw cycle.
The ALP expression was then quantified through the use of the Alkaline Phosphatase
Diethanolamine Activity Kit from Sigma following their protocol. The protocol was amended by
scaling down for use in a 96-well plate. Absorbance was read on a Synergy HT Microplate Reader
from BioTek (Winooski, VT, USA).
4.2.5 Calcium Deposition Quantification
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75%
relative humidity. For the mono-culture study, the osteoblasts were seeded at a density of 2×103
cells/well. For the co-culture study, the undifferentiated Raw 264.7 cells and the osteoblasts were
seeded together (co-culture) at a density of 4×103 cells/well and 2×103 cells/well respectively in
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96-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect
physiologically relevant conditions. These seeding densities allow for comparable particle/cell
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the
culture dish for 24 hours, the cells were treated with different variables as described below.
Two different 7 day studies were conducted with four groups, each done in duplicate, and
designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).
Each treatment was mixed with fresh medium before being added to the cells. The untreated cells
(C) served as the control. The treatment concentrations for the mono-culture experiment were as
follows: 1 µM for free pamidronate (P); ~0.3x1011 particles for G, and GP, that is, ~0.2 µM for
functionalized pamidronate (GP). The treatment concentrations for the co-culture experiment were
as follows: : 3 µM for free pamidronate (P); ~1x1011 particles for G, and GP, that is, ~0.5 µM for
functionalized pamidronate (GP). In the case of samples treated with gold nanoparticle systems,
treatment with 10 and 30 μL of nanoparticle solution was used for the mono-culture and co-culture
respectively. These concentrations correspond to the toxicity thresholds that resulted from earlier
viability studies discussed in Chapter 3. By staying at or below the toxicity threshold, we expect
to remove viability as a variable. A separate control was used for each group so that the volume
ratio of treatment to medium was maintained.
At the end of the treatment period, the spent culture media was removed and the cells were
rinsed with 1x PBS. 50 µL of 5% TCAA was then added to each well in order to dissolve the
calcium over a 90 minute period in an incubator. The dissolved calcium was the quantified through
the use of the Calcium Colorimetric Assay kit from Sigma following the protocol that was
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specified by the kit. Absorbance was read on a Synergy HT Microplate Reader from BioTek
(Winooski, VT, USA). A calibration curve was produced per the manufacturer’s directions and all
results were found to be within the range and linear region of the curve (Figure 4.8).
4.2.6 Calcium Staining
Murine pre-osteoclast cells (RAW 264.7) and murine osteoblast cells (7F2) were recovered
in 1× DMEM (Cellgro, Mediatech, VA, USA) supplemented with 10% (vol/vol) fetal bovine
serum (Sigma) and 1% (vol/vol) antibiotic–antimycotic (Sigma) at 37 ºC, 5% CO2 and 75%
relative humidity. For the mono-culture study, the osteoblasts were seeded at a density of 2×104
cells/well. For the co-culture study, the undifferentiated Raw 264.7 cells and the osteoblasts were
seeded together (co-culture) at a density of 4×104 cells/well and 2×104 cells/well respectively in
6-well plates. Note that the Raw 264.7 cells were not differentiated with RANKL prior to seeding
as the 7F2 osteoblast cells express RANKL and this co-culture was intended to reflect
physiologically relevant conditions. These seeding densities allow for comparable particle/cell
concentrations as seen in the mono-culture experiments. After allowing the cells to attach to the
culture dish for 24 hours, the cells were treated with different variables as described below.
Two different 7 day studies were conducted with four groups, each done in duplicate, and
designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).
Each treatment was mixed with fresh medium before being added to the cells. The untreated cells
(C) served as the control. The treatment concentrations for the mono-culture experiment were as
follows: 1 µM for free pamidronate (P); ~0.3x1012 particles for G, and GP, that is, ~0.2 µM for
functionalized pamidronate (GP). The treatment concentrations for the co-culture experiment were
as follows: : 1 µM for free pamidronate (P); ~1x1012 particles for G, and GP, that is, ~0.5 µM for
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functionalized pamidronate (GP). In the case of samples treated with gold nanoparticle systems,
treatment with 100 and 300 μL of nanoparticle solution was used for the mono-culture and coculture respectively. These concentrations correspond to the toxicity thresholds that resulted from
earlier viability studies discussed in Chapter 3. By staying at or below the toxicity threshold, we
expect to remove viability as a variable. A separate control was used for each group so that the
volume ratio of treatment to medium was maintained.
At the end of the 7 day treatment period cells were fixed with p-formaldehyde at room
temperature for 10 minutes. After rinsing twice with 1x PBS, cells were treated with 2% alizarin
red solution (pH 4.2 using 0.5% ammonium hydroxide) for 30 minutes. The cells were then
thoroughly rinsed to remove any residue and imaged via optical microscopy.
4.2.7 Bone Resorption
Bovine bone slices (Immunodiagnostic Systems, Gaithersburg, MD, US) were first
prepared by rinsing with supplemented DMEM and allowed to soak for half an hour on the last
rinse in order to remove any remaining ethanol. The slices were then place, one in each well, in a
96 well plate prior to seeding with cells.
RANKL-differentiated Raw 264.7 cells were seeded at a density of 4×103 cells/well in the
96-well plate containing the bovine bone slices. After allowing the cells to attach for 24 hours, the
cells were treated with the different variables as described.
Resorption was allowed to take place over 5 days with four groups, each done in duplicate,
and designated as follows: untreated cells (C), cells treated with non-functionalized GNP (G), cells
treated with pamidronate functionalized GNP (GP), and cells treated with free pamidronate (P).
Each treatment was mixed with fresh medium before being added to the cells. The untreated cells
(C) served as the control. For the free pamidronate, osteoclasts were treated with 1 and 5 μM. In
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the case of samples treated with gold nanoparticle systems, treatment with 10 and 50 μL of
nanoparticle solution was used. In each case, the 50 μL volume i.e. the highest treatment
concentration, corresponded to ~4x107 nanoparticles/cell. A separate control was used for each
group so that the volume ratio of treatment to medium was maintained. At the end of the 5 day
treatment period, an enzyme-linked immunosorbent assay (ELISA) was used to quantify type I
collagen in the cell culture supernatants using a CrossLaps® for Culture (CTX-I) ELISA kit from
Immunodiagnostic Systems following the manufacturers protocol and the assay was analyzed on
a Synergy HT Microplate Reader from BioTek (Winooski, VT, USA). A calibration curve was
produced per the manufacturer’s directions and all results were found to be within the range and
linear region of the curve (Figure 4.10).
Pit formation was confirmed at the completion of the study. Briefly, cells were rinsed with
1x PBS and then removed from the bone slices through lysis and sonication using DI water. After
removal of the lysate, 100 µL of toluidine blue (1% dissolved in DI water) was added to each well
and allowed to stain for 1 minute at room temperature. The slices were then rinsed a minimum of
5 times with 250 µL of DI water in order to wash out any residue. Resorption pits were then imaged
with an EVOS FL Cell Imaging System from Invitrogen.
4.2.8 Statistical Analysis
Statistical results are expressed as means +/- SD. Comparisons between data were made
with the use of student’s t-test where significance was determined at p ≤ 0.05.
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4.3 Results and Discussion
4.3.1 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Protein
Expression in Osteoblasts
Figure 4.1 shows the results of the western blot analysis of RANKL expression relative to
b-Actin in the osteoblast cell line. Figure 4.2 shows the corresponding quantitative analysis of the
expression of RANKL relative to β-Actin (P ≤ 0.05). As was previously discussed, RANKL is a
key protein involved in the communication between OB and OC cells and has been shown to be
integral in the bone remodeling process. The results of the western blots, Figures 4.1 and 4.2 show
that there is no effect on RANKL expression in OB cells when treated with the nanoparticles alone
(G) or pamidronate functionalized nanoparticles (GP). However, the results do show an increase
in expression when the cells are treated with GA, P and A, relative to the control.
These results are in general agreement with what has been previously reported in the
literature[14, 15]. Ultimately, these results support that for concentrations at or below the toxicity
threshold, as revealed by the viability studies in Chapter 3, the expression of RANKL is not
impacted by our bisphosphonate functionalized gold nanoparticles. This is an important
consideration when looking at the impact of a potential new treatment, as other changes to normal
cell behavior or performance may result in ultimately the same result as decreased viability.
Maintaining viability in osteoblasts, while decreasing their normal functions, may ultimately still
be a net negative result in relation to shifting the balance of the remodeling process.
Additionally, an investigation into the effect of our nanoparticles systems on the expression
of OPG was also attempted. OPG, expressed on the surface of osteoblasts, is a competitor protein
to RANK that binds RANKL and helps to modulate this recruitment and differentiation process[9],
so it would be insightful to understand this relationship. The results of the study were ultimately
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inconclusive as the OB cell line used in this study did not appear to express sufficient OPG, when
using a positive control to confirm. The 7F2 (CRL-12557 from ATCC) cell line is generally
classified as a mature osteoblast cell line because it has been shown to express alkaline
phosphatase, secrete type I collagen, show a significant cyclic adenosine monophosphate response
to parathyroid hormone, secrete osteocalcin, and mineralize extensively. It is a spontaneously
immortalized cell line isolated from p53-/- mouse bone marrow taken from the femur and
subsequently cloned[16]. This is an example of the difficulty with in vitro studies, as the results
can vary widely based on a number of factors, including cell lines that are not primary. Further
investigation into the effect of bisphosphonate functionalized gold nanoparticles on this
OPG/RANKL system would be of interest.
4.3.2 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Alkaline
Phosphatase Expression
Figure 4.3 shows the results of the alkaline phosphatase assay with values relative to
control (C, P ≤ 0.05). The results show that there is no difference across all treatments when
compared to the control. This is supported in the literature for the concentration range studied in
the experiment[17]. The concentrations used in this study should eliminate viability as a variable
based on the results presented in Chapter 3. Alkaline phosphatase is an enzyme which is attached
to the outer face of the plasma membrane (an ectoenzyme) in vertebrates[18]. Humans have four
ALP genes including one that corresponds to liver/bone/kidney gene products [19], which is
classified as tissue non-specific. The role of ALP in bone mineralization was first proposed more
than 8 decades ago, and is well established today. ALP acts through a catalytic mechanism to
increase the local concentration of inorganic phosphate[20]. Additionally, mineralization of the
new bone tissue has been repeated shown to be preceded by measurement of high levels of ALP
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expression, during the pursuit of novel tissue engineering constructs[21-23]. The results here
support the notion that if a concentration is targeted that does not affect cell viability, it can also
be expected to not affect other key behavior, specifically, expression of alkaline phosphatase. This
indicates that normal osteoblast performance for bone mineralization could be maintained.
4.3.3 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Bone Nodule
Formation
Figure 4.4 shows the results of the calcium quantification analysis of bone nodule
formation by the osteoblast cell line in mono-culture relative to control (P ≤ 0.05). Figure 4.5
shows the complementary alizarin red staining of the bone nodule formation in vitro, where the
arrows indicate bone nodule formations. Alizarin red reacts with calcium, resulting in a red/orange
stain, thereby identifying calcium deposits[24]. The results of the quantitative analysis in Figure
4.4 show that there is no effect on bone nodule formation by OB cells across all treatment variables
at the concentrations studied. This is supported by past study by Orriss et al [10], where they also
saw no decrease in nodule formation with 1 µM pamidronate. As discussed before, the
concentrations used in this study should eliminate viability as a variable based on the results
presented in Chapter 3 and this is supported by these results. The results in Figure 4.4 are also
supported by the images in Figure 4.5, where no qualitative difference can be determined. The
arrows in Figure 4.5 indicate a few examples of bone nodules, which show as strong orange/red
color. Additionally, this is in agreement with the previously discussed ALP expression study,
which would be consistent with no change in mineralization behavior.
Figure 4.6 shows the results of the calcium quantification analysis of bone nodule
formation by the osteoblast cell line in co-culture with the osteoclast cell line, relative to control
(P ≤ 0.05). Figure 4.7 shows the complementary alizarin red staining of the bone nodule formation
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in vitro. Similar to the results in Figure 4.5, Figure 4.6 also shows that there is no effect on bone
nodule formation by OB cells across all treatment variables at the concentrations studied, when
co-cultured with osteoclasts. This is supported by the images in Figure 4.7, where no qualitative
difference can be determined. However, by comparing Figure 4.5 and 4.6, it is obvious that the
inclusion of the osteoclasts affects the degree of mineralization. The bone nodules in each figure
differ significantly (see arrows for guidance). The nodules in Figure 4.5 are larger and more
concentrated (indicated by strong staining) than those in Figure 4.6. This is a good representation
of the bone remodeling process and the balance between bone deposition and bone resorption. As
the OB cells are mineralizing, the OC cells are simultaneous resorbing, producing less distinct
nodule formation and wider distribution of calcium throughout the plate.
4.3.4 Effect of Bisphosphonate Functionalized Gold Nanoparticles on Bone
Resorption
Figure 4.9 shows the results of the analysis of bone resorption on bovine bone slices by
osteoclasts, via quantification of type I collagen in the cell supernatant, when treated with two
different concentrations. As discussed previously, osseous tissue is made up of various inorganic
salts as well as collagen[25]. Type I collagen accounts for more than 90% of the organic matrix of
bone, fragments of which are released during the bone remodeling process. Note that these
treatment concentrations correspond to the lowest and highest concentrations investigated in the
osteoclast viability study discussed in Chapter 3. Figure 4.11 is a representative image of
confirmation of resorption pit formation through toluidine blue staining. The results in Figure 4.9
indicated that there is no difference in any treatment compared to its control (P ≤ 0.05) with the
exception of the 5 µM free bisphosphonate treatment. The 1 µM treatments agree with the viability
data presented in Chapter 3 which showed no decrease in cell viability, as a decrease in viability
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should correspond to a decrease in bone resorption. However, the 5 µM treatment does not agree
with the previous viability data. That viability data showed a decrease in cell viability when treated
with the corresponding pamidronate functionalized GNP. However, it is important to note that the
viability was not considered in the presence of bone.
Bisphosphonates have been shown to be readily attracted to and strongly adherent to
bone/hydroxyapatite[26]. This feature has even been leveraged as a targeting method for
microcalcifications in breast tissue for contrast enhanced X-ray[27, 28]. With the potential
interaction between the bisphosphonates, both on the surface of the gold and in free form, this may
lead to a change in the uptake of the pharmaceutical in the presence of bone. The significantly lower
concentration of bisphosphonate on the surface of the gold as determine through ICP-MS discussed
in Chapter 2 may have ultimately led to the difference seen in this study. As the osteoclasts resorb
the bone surface and uptake bisphosphonate that may be interacting with the bone, the advantage
may conceivably be with the treatment having higher total bisphosphonate availability, which in
this case would be the 5 µM free bisphosphonate treatment over the ~3 µM bound bisphosphonate
in the pamidronate functionalized gold nanoparticle treatment. This premise is supported in the
literature. A study by Schindeler et al. [29] where they cultured osteoblasts and osteoclast separately
on phosphate coated quartz disks that were pretreated with zoledronic acid, showed that although
osteoclasts were negatively influenced by this substrate, osteoblasts were largely unaffected. In fact,
they went on to proliferate, and produce a mineralized matrix. Similar results were shown by
Panzavolta et al.[30]. This adherence to bone surfaces could act as an additional avenue for uptake
in OC cells, as only OC cells resorb the bone surface. This strong interaction with bone is an
important consideration in further developing potential treatments for osteoporotic disease.
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Figure 4.1 Western blot results (in duplicate) of RANKL and β-actin expression in osteoblast cells.
The treatment concentrations were as follows: 1.5 µM for free pamidronate (P) and alendronate
(A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2 µM for pamidronate (GP) and 0.9
µM alendronate (GA).
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Figure 4.2 Quantitative analysis of the expression of RANKL relative to β-actin from the western
blot. The treatment concentrations were as follows: 1.5 µM for free pamidronate (P) and
alendronate (A); 0.5x1011 particles for G, GP, and GA samples that is, 0.2 µM for pamidronate
(GP) and 0.9 µM alendronate (GA). Asterisk denotes a significant difference P ≤ 0.05 relative to
control.
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Figure 4.3 Quantitative analysis of the expression of ALP by osteoblasts. The treatment
concentrations were as follows: 1 µM for free pamidronate (P) and alendronate (A); ~0.3x1011
particles for G, GP, and GA, that is, ~0.2 µM for functionalized pamidronate (GP) and ~0.6 µM
for functionalized alendronate (GA). Values were compared to control (C, P ≤ 0.05).
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Figure 4.4 Quantitative analysis of the bone nodule formation in mono-culture of osteoblasts.
Bone nodule formation was quantified through the quantification of calcium present in each
sample. The treatment concentrations were as follows: 1 µM for free pamidronate (P); ~0.3x1011
particles for G, and GP, that is, ~0.2 µM for functionalized pamidronate (GP). Values were
compared to control (C, P ≤ 0.05).
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Figure 4.5 Alizarin red staining of bone nodule formation in mono-culture of osteoblasts at 10x
magnification. Arrows indicate some of the nodule formations. Measure dot indicates 150 µm.
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Figure 4.6 Quantitative analysis of the bone nodule formation in co-culture of osteoblasts with
osteoclasts. Bone nodule formation was quantified through the quantification of calcium present
in each sample. The treatment concentrations were as follows: 3 µM for free pamidronate (P);
~1x1011 particles for G, and GP, that is, ~0.5 µM for functionalized pamidronate (GP).Values were
compared to control (C, P ≤ 0.05).
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Figure 4.7 Alizarin red staining of bone nodule formation in co-culture of osteoblasts with
osteoclasts at 5x magnification. Arrows indicate some of the nodule formations. Measure dot
indicates 150 µm.
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Figure 4.8 Calibration curve for calcium colorimetric assays.
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Figure 4.9 Quantitative analysis of the bone resorption by osteoclasts. Bone resorption was
analyzed by quantification of type I collagen release from bovine bone slices due to resorption.
Here 100% treatment corresponds to 5 μM free pamidronate (P), ∼1.6 × 1011 particles gold

nanoparticles alone (G) and pamidronate functionalized nanoparticles (GP), which corresponds to
∼0.8 μM pamidronate on gold (GP). Asterisk denotes a significant difference (P ≤0.05) relative to
control (C).
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Figure 4.10 Calibration curve for ELISA assay of bone resorption.
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Figure 4.11 Representative image of resorption pit formation. Pit formation on bovine bone slices
was confirmed via toluidine blue staining. Figure A was not seeded with osteoclasts and shows a
lack of resorption pits. Arrows in Figure B indicate some of the resorption pits formed by
osteoclasts. Image is at 10x magnification and measure bar indicates 400 µm.
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CHAPTER 5:
SUMMARY, CONCLUSIONS AND FUTURE WORK
5.1 Summary and Conclusions
In this doctoral research, we have synthesized and studied the effect of bisphosphonate
functionalized gold nanoparticles on in vitro cell cultures, toward the development of a potential
new treatment and means of study, for osteoporotic bone disease. First, we synthesized and
characterized the bisphosphonate functionalized gold nanoparticles, including quantification of
bound bisphosphonates on the surface of the gold. We then took a look at the effect of these
bisphosphonate functionalized gold nanoparticles on cell viability and morphology compared to
free bisphosphonate delivery. Finally, we analyzed the effect of these gold nanoparticle systems
on other key cell behavior and activity, including protein expression and bone remodeling.
In Chapter 2, a detailed description was given on the synthesis and characterization of
bisphosphonate functionalized gold nanoparticles. Gold nanoparticles were synthesized with size
of approximately 15 nm, which are suitable for cellular uptake, and then the surface was
functionalized using self-assembly, with pamidronate and alendronate. Microscopy, spectroscopy,
and scattering techniques were used to gain insight into the particle size distribution, shape, and to
help confirm surface modification with bisphosphonates. In an important advance compared to
past studies, inductively coupled plasma mass spectrometry was used to measure the surface
density of the bisphosphonates on the gold nanoparticles, being approximately 0.65 molecules per
nm2 (approximately 154 Å2/molecule) for GP and approximately 2.6 molecules per nm2
(approximately 39 Å2/molecule) for GA. This allows for more accurate estimates of
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pharmaceutical concentrations, when comparing to free bisphosphonates, which is important when
comparing results of in vitro and in vivo studies.
In Chapter 3, we investigated the effects of bisphosphonate functionalized gold
nanoparticles on the viability and morphology of osteoclast and osteoblast cells in vitro. The
various in vitro studies included mono-cultures of osteoclasts and of osteoblasts as well as more
physiologically relevant co-cultures that relied on the RANKL expression of osteoblasts to
differentiate the Raw 264.7 pre-osteoclast cells. We found that attaching the bisphosphonates to
the surface of the nanoparticles leads to increased apoptotic effects of the bisphosphonates on the
osteoclast cells compared to free bisphosphonates. This is important, as the surface density
discussed in Chapter 2 shows that we have much lower concentrations of bisphosphonates when
bound to the surface of the gold. This result is likely explained by the endocytotic nature of
osteoclasts. Further, we showed bisphosphonate functionalized gold nanoparticles may have an
effect on nuclei morphology, which may provide an additional means of modulating bone
resorption rather than just through viability. Finally, we showed that it may be possible to target a
concentration that is safe for osteoblasts, which is critical in determining potential treatment
concentrations. However, it is clear that under more physiologically accurate conditions, these
results are much more difficult to separate. These viability results bring to light a number of
potential considerations in the optimization of potential treatments, such as dosing and in vitro
versus in vivo concentrations.
Chapter 4 detailed results on effects of bisphosphonate functionalized gold nanoparticles
on important behavior and activity of osteoclast and osteoblast cells in vitro. The objective was to
analyze the effect that functionalized nanoparticles have on expression of key proteins and
enzymes in the osteoclast-osteoblast interplay. Additionally, the effect surface-modified
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nanoparticles have on mineral deposition and bone resorption performance was also detailed. A
number of different techniques were used to quantify RANKL and alkaline phosphatase expression
in osteoblasts, as well as calcium deposition. Various staining and imaging techniques were used
to observe calcium nodule formation and resorption pits in bovine bone slices. We showed that
while using concentrations below the toxicity threshold, some of the normal activity of the cells
could be maintained. RANKL and ALP expression in osteoblasts were maintained when removing
viability as a variable. Additionally, bone nodule formation was also maintained for osteoblasts
and co-cultured in vitro systems. Finally, we showed that the introduction of bone in the in vitro
studies adds a new degree of consideration as to the interaction of the bisphosphonates with the
hydroxyapatite surface. This strong interaction with bone is an important consideration in further
developing potential treatments for osteoporotic disease.
Overall, this dissertation provides insights into the use of bisphosphonate functionalized
gold nanoparticles as a potential treatment and means of study for bone remodeling disorders. In
addition, this dissertation has helped to highlight the different considerations necessary when
studying a potential new treatment.
5.2 Future Work
We believe that the research pursued in this doctoral project lays the groundwork for future
work on the development of gold nanoparticle based treatments for osteoporotic disease.
Throughout this dissertation, we discussed a number of important considerations moving forward
to the development of a potential treatment. Some of these considerations include:
•

concentrations comparisons in vitro versus in vivo

•

cell lines used in in vitro studies

•

the stability of these nanoparticle systems in vitro and in vivo
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•

the effect bisphosphonate interaction with bone plays in the deployment of
bisphosphonate functionalized gold nanoparticles as a treatment

Towards these ends, we present the following considerations for potential future work.
In Vitro studies are a good way to lay the foundation for any new treatment. However, the
logical next step would be studies involving animal models. These investigations would address
many of the previously describe issues. Differences in cell lines would no longer be a concern.
Although, we would still ultimately contend with the issue of translating disease treatment from
animal model to human, eventually. Furthermore, animal models would allow for significantly
greater physiological complexity than could be achieved in any in vitro study. It would also allow
more direct investigation into local concentrations in vivo and address the issue of having to
translate in vitro concentrations to what is experienced in vivo. The application of similar
bisphosphonate functionalized gold nanoparticles has been shown in detection of breast
microcalcifications using contrast-enhanced X-ray when injected into a murine model of breast
cancer [1, 2]. There are a number of animal models available for the study of osteoporosis, which
have been vetted thoroughly in the literature[3]. Ultimately, investigation of the effects of
bisphosphonate functionalized gold nanoparticles in vivo would go the furthest in addressing many
of the issues discussed in this dissertation.
There remains a concern with the stability of the bisphosphonate functionalized gold
nanoparticles as designed. Due to the relatively weak interaction between the primary amine group
of the bisphosphonates and the surface of the gold [4, 5], introduction into an in vivo system may
lead to instability. This would likely be cause by extracellular components in the blood stream or
tissue after introduction into the body. Additionally, if we were able to increase the residence time,
we may be able to decrease dosing frequency and concentration. A promising way of approaching
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these issues is through the application of a biodegradable polymer coating. Some studies have
shown promising results with the incorporation of SPIO in biodegradable polymer for magnetic
resonance imaging [6-8], which can conceivably be applied to our GNP systems. PEGylation,
which is the modification of nanoparticle surfaces by the addition of polyethylene glycol (PEG),
is the most commonly used method for reducing premature clearance of NPs from the body[9].
This approach is typically termed “stealthing”. An additional benefit of PEGylation and other
similar polymer coating approaches, is the ability to load the pharmaceutical of interest in the
polymer[10]. The drug is released as the polymer degrades, and has the added benefit of
significantly stabilizing the nanoparticle system. The modification of our gold nanoparticle system
by addition of a polymer coating would be beneficial next step toward a potent new treatment.
5.3 References
1.

Cole, L.E., T. Vargo-Gogola, and R.K. Roeder, Contrast-Enhanced X-ray Detection of
Breast Microcalcifications in a Murine Model Using Targeted Gold Nanoparticles. ACS
Nano, 2014. 8(7): p. 7486-7496.

2.

Cole, L.E., T. Vargo-Gogola, and R.K. Roeder, Bisphosphonate-functionalized gold
nanoparticles for contrast-enhanced X-ray detection of breast microcalcifications.
Biomaterials, 2014. 35(7): p. 2312-2321.

3.

Turner RT, M.A., Lotinun S, Hefferan T, Evans GL, Zhang M, Sibonga JD., Animal models
for osteoporosis. Rev Endocr Metab Disord, 2001. 2(1): p. 117-27.

4.

Kumar, A., et al., Investigation into the interaction between surface-bound alkylamines
and gold nanoparticles. Langmuir, 2003. 19(15): p. 6277-6282.

5.

Leff, D.V., L. Brandt, and J.R. Heath, Synthesis and Characterization of Hydrophobic,
Organically Soluble Gold Nanocrystals Functionalized with Primary Amines. Langmuir,
1996. 12(20): p. 4723-4730.

6.

Veiseh O, G.J.W., Zhang M, Design and fabrication of magnetic nanoparticles for targeted
drug delivery and imaging. Advanced Drug Delivery Reviews, 2010. 62(3): p. 284–304.

7.

Ling Y, W.K., Luo Y, Gao X, Zhong S, Dual docetaxel/superparamagnetic iron oxide
loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy.
Biomaterials, 2011. 32: p. 7139-7150.

97

8.

Wang Y, N.Y., Chen Y, Shuter B, Yi J, Ding J, Wang S, Feng S, Formulation of
Superparamagnetic Iron Oxides by Nanoparticles of Biodegradable Polymers for
Magnetic Resonance Imaging. Adv. Funct. Mater., 2008. 18: p. 308–318.

9.

Yeo, Z.A.a.Y., Recent advances in stealth coating of nanoparticle drug delivery systems.
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2012. 4(2): p. 219-233.

10.

Karel Ulbrich, K.H., Vladimir Šubr, Aristides Bakandritsos, Jiří Tuček, and Radek Zbořil,
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and
Noncovalent Approaches, Release Control, and Clinical Studies. Chem. Rev., 2016.
116(9): p. 5338-5431.

98

APPENDICES

99

Appendix A: List of Abbreviations
GNP

Gold nanoparticle

LSPR

Localized surface plasmon resonance

DMEM

Dulbecco’s modified eagle medium

PBS

Phosphate buffer saline

FBS

Fetal bovine serum

DLS

Dynamic light scattering

BP

Bisphosphonate

nBP

Nitrogen containing bisphosphonate

ALN

Alendronate

PAM

Pamidronate

RANK

Receptor activator of nuclear factor kappa-B

RANKL

Receptor activator of nuclear factor kappa-B ligand

MTT

Methylthiazol tetrazolium

OPG

Osteoprotegerin

OC

Osteoclast

OB

Osteoblast

ALP

Alkaline phosphatase

ICP-MS

Inductively coupled plasma mass spectrometry

ELISA

Enzyme-linked immunosorbent assay

UV-vis

Ultra violet – visible

PEG

Polyethylene glycol
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